These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
539 related articles for article (PubMed ID: 23910030)
1. Prevention of meningococcal infections in the first 2 years of life. Woods CR Pediatr Ann; 2013 Aug; 42(8):164-71. PubMed ID: 23910030 [TBL] [Abstract][Full Text] [Related]
2. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). Cohn AC; MacNeil JR; Clark TA; Ortega-Sanchez IR; Briere EZ; Meissner HC; Baker CJ; Messonnier NE; MMWR Recomm Rep; 2013 Mar; 62(RR-2):1-28. PubMed ID: 23515099 [TBL] [Abstract][Full Text] [Related]
3. MenACWY-TT vaccine for active immunization against invasive meningococcal disease. Papaevangelou V; Spyridis N Expert Rev Vaccines; 2012 May; 11(5):523-37. PubMed ID: 22827239 [TBL] [Abstract][Full Text] [Related]
4. Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons - Advisory Committee on Immunization Practices, 2016. MacNeil JR; Rubin LG; Patton M; Ortega-Sanchez IR; Martin SW MMWR Morb Mortal Wkly Rep; 2016 Nov; 65(43):1189-1194. PubMed ID: 27811836 [TBL] [Abstract][Full Text] [Related]
5. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. Mbaeyi SA; Bozio CH; Duffy J; Rubin LG; Hariri S; Stephens DS; MacNeil JR MMWR Recomm Rep; 2020 Sep; 69(9):1-41. PubMed ID: 33417592 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model. Vickers DM; Anonychuk AM; De Wals P; Demarteau N; Bauch CT Vaccine; 2015 Jan; 33(1):268-75. PubMed ID: 24103896 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE; Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028 [TBL] [Abstract][Full Text] [Related]
8. Meningococcal vaccine evolution. Bona G; Guidi C J Prev Med Hyg; 2012 Sep; 53(3):131-5. PubMed ID: 23362617 [TBL] [Abstract][Full Text] [Related]
9. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States. Lingappa JR; Rosenstein N; Zell ER; Shutt KA; Schuchat A; Perkins BA; Vaccine; 2001 Aug; 19(31):4566-75. PubMed ID: 11483285 [TBL] [Abstract][Full Text] [Related]
10. Present situation and new perspectives for vaccination against Neisseria meningitidis in Tuscany, Central Italy. Bechini A; Levi M; Boccalini S; Tiscione E; Ceccherini V; Taddei C; Balocchini E; Bonanni P J Prev Med Hyg; 2012 Jun; 53(2):61-7. PubMed ID: 23240162 [TBL] [Abstract][Full Text] [Related]
11. Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2013 Jan; 62(3):52-4. PubMed ID: 23344698 [TBL] [Abstract][Full Text] [Related]
12. Changes in the Population Structure of Invasive Neisseria meningitidis in the United States After Quadrivalent Meningococcal Conjugate Vaccine Licensure. Wang X; Shutt KA; Vuong JT; Cohn A; MacNeil J; Schmink S; Plikaytis B; Messonnier NE; Harrison LH; Clark TA; Mayer LW J Infect Dis; 2015 Jun; 211(12):1887-94. PubMed ID: 25556253 [TBL] [Abstract][Full Text] [Related]
13. Current Epidemiology and Trends in Meningococcal Disease-United States, 1996-2015. MacNeil JR; Blain AE; Wang X; Cohn AC Clin Infect Dis; 2018 Apr; 66(8):1276-1281. PubMed ID: 29126310 [TBL] [Abstract][Full Text] [Related]
15. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation. Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880 [TBL] [Abstract][Full Text] [Related]
16. [Meningococcal vaccines: from polysaccharide to conjugate vaccines]. Cohen R; Levy C Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368 [TBL] [Abstract][Full Text] [Related]
17. Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2013. MacNeil JR; Rubin L; McNamara L; Briere EC; Clark TA; Cohn AC; MMWR Morb Mortal Wkly Rep; 2014 Jun; 63(24):527-30. PubMed ID: 24941332 [TBL] [Abstract][Full Text] [Related]
18. Use of the Pfizer Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. Collins JP; Crowe SJ; Ortega-Sanchez IR; Bahta L; Campos-Outcalt D; Loehr J; Morgan RL; Poehling KA; McNamara LA MMWR Morb Mortal Wkly Rep; 2024 Apr; 73(15):345-350. PubMed ID: 38635488 [TBL] [Abstract][Full Text] [Related]
19. Protecting the most vulnerable age group: a review of MenACWY-TT immunogenicity and safety in infants. Martinón-Torres F; Serra L; Safadi MAP Expert Rev Vaccines; 2020 Apr; 19(4):313-325. PubMed ID: 32250710 [TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Perrett KP; Snape MD; Ford KJ; John TM; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ Pediatr Infect Dis J; 2009 Mar; 28(3):186-93. PubMed ID: 19209097 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]